Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab.
Anti-VEGF
Brolucizumab
Cystoid macular edema
Radiation maculopathy
Retinoblastoma
Journal
American journal of ophthalmology case reports
ISSN: 2451-9936
Titre abrégé: Am J Ophthalmol Case Rep
Pays: United States
ID NLM: 101679941
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
26
08
2020
revised:
12
10
2020
accepted:
20
10
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
5
11
2020
Statut:
epublish
Résumé
To assess the efficacy of intravitreal brolucizumab (Beovu®, Novartis Pharmaceuticals) in a case of recalcitrant cystoid macular edema associated with radiation maculopathy secondary to retinoblastoma which was suboptimally responsive to other intravitreal anti-vascular endothelial growth factor (VEGF) therapies. A 42-year old patient with a history of radiation maculopathy complicated by cystoid macular edema after chemoreduction treatment and radiation therapy for retinoblastoma was treated with intravitreal brolucizumab. Best-corrected visual acuity and central macular thickness assessed by optical coherence tomography were used to assess the clinical outcomes. The treated eye was also assessed for evidence of intraocular inflammation following injection. Cystoid macular edema showed marked reduction and near resolution two weeks after injection and improvement in best-corrected visual acuity which was maintained for 2 months of follow-up. No ocular inflammatory reactions or other adverse events were reported. This case of radiation maculopathy refractory to other intravitreal anti-VEGF treatments showed good treatment response to brolucizumab therapy.
Identifiants
pubmed: 33145457
doi: 10.1016/j.ajoc.2020.100981
pii: S2451-9936(20)30296-6
pmc: PMC7595878
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100981Informations de copyright
© 2020 Published by Elsevier Inc.
Déclaration de conflit d'intérêts
SriniVas Sadda: Amgen (C), Allergan (C), Genentech-Roche (C), Oxurion (C), Novartis (C), Regeneron (C), Bayer (C), 4DMT (C), Centervue (C, S), Heidelberg (C, F, S), Optos (C, F, S), Carl Zeiss Meditec (F, S), Nidek (S), Topcon (S); the following authors have nothing to disclose: GC, FC, AJ.
Références
Ophthalmology. 1998 Aug;105(8):1425-9
pubmed: 9709753
Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):765-73
pubmed: 7960977
Dev Ophthalmol. 2010;46:123-132
pubmed: 20703038
Retin Cases Brief Rep. 2007 Fall;1(4):198-201
pubmed: 25390976
Ophthalmology. 2006 Nov;113(11):2087-92
pubmed: 16949158
Retina. 2005 Oct-Nov;25(7):868-74
pubmed: 16205566
Arch Ophthalmol. 2010 Feb;128(2):249-52
pubmed: 20142553
Retin Cases Brief Rep. 2014 Summer;8(3):167-70
pubmed: 25372430
Ocul Oncol Pathol. 2018 Apr;4(3):157-160
pubmed: 29765946
Eye (Lond). 1991;5 ( Pt 2):239-51
pubmed: 2070883
Am J Ophthalmol Case Rep. 2020 Jul 02;19:100815
pubmed: 32671288